SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 31, 2012
BIOCUREX, INC.
-------------------------------
(Name of Small Business Issuer in its charter)
Texas 0-26947 75-2742601
--------------------- ------------------ ------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
7080 River Road, Suite 215
Richmond, British Columbia , Canada V6X 1X5
------------------------------------------
(Address of Principal Executive Offices, including Zip Code)
Registrant's telephone number, including area code: (866) 884-8669
N/A
-----------------------------
(Former name or former address if changed since last report)
Item 5.07. Submission of Matters to a Vote of Securities Holders.
A special meeting of Biocurex's shareholders was held on July 31, 2012. At
the meeting the following proposals were ratified by the shareholders:
(1) to approve an amendment to the Company's Articles of Incorporation to
authorize the Company to issue up to 10,000,000 shares of preferred stock, with
the Company's directors having the right to issue the preferred stock in one or
more series, and to establish the rights and preferences of each series; and
(2) to approve a resolution to amend the Company's Articles of
Incorporation which would reverse split the Company's common stock by a ratio
that will be determined by the Company's Board of Directors. At any time prior
to the time the Articles of Amendment take effect, the Board of Directors may
abandon the proposed stock split without further action by the shareholders.
The following is a tabulation of votes cast with respect to these
proposals:
Votes
------------------------------------- Broker
Proposal For Against Abstain Non-Votes
1. 147,813,892 10,526,734 1,586,946 --
2. 217,054,592 28,121,825 459,250 --
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 1, 2012 BIOCUREX, INC.
By:/s/ Dr. Ricardo Moro
-------------------------------------
Dr. Ricardo Moro, Chief Executive
Officer
